Abstract:1563 Aim: Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a severe but treatable autoimmune disease. The occurrence of anti-NMDAR encephalitis is associated with presence of specific antibodies against NMDAR in central nervous system. So far, several trigger factors were postulated in relation to the development of disease, which are paraneoplastic (especially associated with ovarian teratoma), viral encephalitis-related and cryptogenic. Each type is different in clinical course, treatment strategies and prognosis. This study aims to explore distinct cerebral metabolic abnormalities in patients with anti-NMDAR encephalitis triggered by different factors and its clinical correlates. Methods: Twenty-four patients with anti-NMDAR encephalitis in acute phase from Huashan Hospital, Shanghai were recruited. All patients were diagnosed based on positive antibodies in serum and CSF. We reviewed patients’ imaging features (including brain MRI and 18F-FDG PET) together with clinical information. Each patient was classified into an etiological subgroup. Results: Of the twenty-four patients (17 male, 7 female; median age: 21 years) with anti-NMDAR encephalitis included in this study, thirteen were divided into the cryptogenic group, five patients with ovarian teratomas were divided into the paraneoplastic group and the remaining six were viral encephalitis-related. We found that patients’ onset age, maximum modified Rankin Scale (mRS) had no statistical difference among three groups (all P > 0.05). CSF protein level in viral encephalitis-related group was significantly higher than that in paraneoplastic group and cryptogenic group (P 0.05). For MRI imaging, we observed an overall 50% of all patients presenting with abnormal MRI. Specifically, only three of the thirteen patients in cryptogenic group, three of the five patients in paraneoplastic group, but all patients in viral encephalitis-related were observed with abnormal MRI signals. For 18F-FDG PET imaging, we noted that 100% patients have abnormalities on PET scans, with frontal-temporal-occipital lobes and basal ganglia as the most frequently affected regions. Three subgroups demonstrated distinct characteristics in 18F-FDG PET scans. Both groups of patients with cryptogenic and paraneoplastic anti-NMDAR encephalitis showed bilateral hypermetabolism in the frontal-temporal lobes and basal ganglia, covarying with bilateral hypometabolism in the occipital regions. Notably, the changes of hypermetabolism in the cortical and subcortical regions were usually asymmetric in the patients with cryptogenic encephalitis, but relative symmetric in those associated with tumor. In patient group secondary to viral encephalitis, focal reductions of metabolism in unilateral cerebral cortex were found, mostly affecting the unilateral temporal lobe and part of basal ganglia (the same regions with abnormal signal on MRI), accompanied by slight hypermetabolism in the contralateral temporal regions. Conclusion: This study gave detailed description of distinct brain metabolic abnormalities related to patients with anti-NMDAR encephalitis triggered by different causes. The awareness of such distinct patterns gave an insight to investigate anti-NMDAR encephalitis from a new etiological perspective which might be useful to facilitate early diagnosis, and more importantly, to promote treatment strategies.

Colocalization of Increased Midbrain Signals in Neuroinflammation and Tau PET Imaging Suggests the Diagnosis of Progressive Supranuclear Palsy

Microglial Activation Imaging Using 18F-DPA-714 PET/MRI for Detecting Autoimmune Encephalitis.

Activated microglia by 18F-DPA714 PET in a case of anti-LGI1 autoimmune encephalitis

18F-DPA714 PET/MRI as a potential imaging tool for detecting possible antibody-negative autoimmune encephalitis: a prospective study

Microglial Activation Imaging Using 18 F-DPA-714 PET/MRI for Detecting Autoimmune Encephalitis

Characterization of Neuroinflammation Pattern in Anti-Lgi1 Encephalitis Based on TSPO PET and Symptom Clustering Analysis

Tau-PET imaging in Parkinson's disease: a systematic review and meta-analysis

Characterization of microglia activation patterns in anti-LGI1 encephalitis based on TSPO PET and symptom clustering analysis

Clinical and imaging analysis to evaluate the response of patients with anti-DPPX encephalitis to immunotherapy

Advances in the diagnosis and treatment of dipeptidyl-peptidase-like protein 6 antibody-associated encephalitis

Anti-dipeptidyl-peptidase-like Protein 6 Encephalitis, a Rare Cause of Reversible Rapid Progressive Dementia and Insomnia

Imaging glial activation in patients with post-treatment Lyme disease symptoms: a pilot study using [11C]DPA-713 PET

Expanding the clinical spectrum of anti-DPPX encephalitis: a multicenter retrospective study

The clinical and predictive value of 18F-FDG PET/CT metabolic patterns in a clinical Chinese cohort with autoimmune encephalitis

In Vivo Measurement of Tau Depositions in Anti-IgLON5 Disease Using [18F]PI-2620 PET

Pet Imaging For Dynamically Monitoring Neuroinflammation In App/Ps1 Mouse Model Using [F-18]Dpa714

PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes

Clinical Utility of 18F‐APN‐1607 Tau PET Imaging in Patients with Progressive Supranuclear Palsy

Brain 18F-FDG PET Imaging in Patients with Anti-N-methyl-D-aspartate Receptor Encephalitis Triggered by Different Factors: Cerebral Metabolic Abnormalities and Clinical Correlates

Distinct Cerebral 18F-FDG PET Metabolic Patterns in Anti-N-methyl-d-aspartate Receptor Encephalitis Patients with Different Trigger Factors

[IC-03-02]: [11 C]PK11195 PET IN ALZHEIMER's DISEASE AND PROGRESSIVE SUPRANUCLEAR PALSY: THE NIMROD STUDY